Study of MRI ADC and Radiomic Features to Detect Prostate Cancer Tumor Lesions

What this Trial Is About

Researchers are conducting an observational study to explore if analyzing ADC values and radiomic features from multiparametric MRI images can help detect prostate cancer. This study includes patients who underwent these imaging procedures at IRCCS Azienda Ospedaliero-Universitaria hospital in Bologna between September 2015 and March 2021. The main goal is to determine whether these imaging characteristics improve identification of prostate tumor lesions. Participants will have their radiological data collected by radiologists, clinical data by urologists, and histological data by anatomo-pathologists. ADC values from suspicious lesions and healthy prostate tissue will be extracted from MRI scans. Radiomic characteristics will be analyzed after images are anonymized and processed by medical physicists and engineers at the University of Bologna. All data will be stored securely in a shared database. During the study, the distribution of ADC values will be tracked from enrollment through up to four years. Study involvement includes consent, collection of imaging and clinical data, and analysis of MRI features. The research team will review these imaging markers to understand their role in identifying clinically significant prostate cancer lesions, with data kept confidential throughout the process.

Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions